Cargando…

Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer

Drug treatment of 3D cancer spheroids more accurately reflects in vivo therapeutic responses compared to adherent culture studies. In EGFR-mutated lung adenocarcinoma, EGFR-TKIs show enhanced efficacy in spheroid cultures. Simultaneous inhibition of multiple parallel RTKs further enhances EGFR-TKI e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theard, Patricia L, Sheffels, Erin, Sealover, Nancy E, Linke, Amanda J, Pratico, David J, Kortum, Robert L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2020
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478890/ https://www.ncbi.nlm.nih.gov/pubmed/32897190 http://dx.doi.org/10.7554/eLife.58204

Ejemplares similares

SOS2 regulates the threshold of mutant EGFR-dependent oncogenesis
por: Theard, Patricia L., et al.
Publicado: (2023)

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
por: Wang, Jinguang, et al.
Publicado: (2018)

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
por: Zeng, Hao, et al.
Publicado: (2019)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
por: Ianza, Anna, et al.
Publicado: (2021)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
por: Wang, Huijuan, et al.
Publicado: (2019)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients
por: He, Changlong, et al.
Publicado: (2021)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
por: Garrido, Pilar, et al.
Publicado: (2021)

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
por: Chua, Khi Pin, et al.
Publicado: (2021)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
por: Seki, Nobuhiko, et al.
Publicado: (2019)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth
por: Niu, Mengmeng, et al.
Publicado: (2021)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
por: de Langen, Adrianus J., et al.
Publicado: (2018)

Current Approaches in NSCLC Targeting K-RAS and EGFR
por: Aran, Veronica, et al.
Publicado: (2019)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8e758tq0h481shcokmoi2lmt9s